When comparing the sarcopenia group with the nonsarcopenia group in terms of glucose-lowering treatments (metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitors, DPP4 inhibitors, insulin, basal + bolus insulin, basal insulin, and premixed insulin), there was no discernible statistically significant change (Table 1). Here, SLC5A2 is linked to sarcopenia.